Beijing Wantai Biological Pharmacy Enterprise (603392.SS)

Overall impact
B (71)

Commentary

Beijing Wantai Biological Pharmacy Enterprise is a strong overall performer. With a 'B' rating of 70.8 for overall impact (83rd percentile compared to all companies), Beijing Wantai Biological Pharmacy Enterprise ranks 257th out of 585 industry peers, behind Biogen, Amgen, Biomarin Pharmaceutical and 253 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 325 others. On top material causes for Beijing Wantai Biological Pharmacy Enterprise's industry (Pharmaceuticals & Biotech), Beijing Wantai Biological Pharmacy Enterprise performs well in Access to Affordable Healthcare (85.5 score), Technology Innovation (95.1), Improved Mental Health (90.7) and 1 other cause where it received an 'A' score and performs poorly in Reduced Use of tobacco (38.3 score).
Impact
Cause 603392.SS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Beijing Wantai Biological Pharmacy Enterprise

Employees
4,116
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
China
Share classes
603392.SS
Description
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.
Material causes
Ethos considers the following causes material for Beijing Wantai Biological Pharmacy Enterprise, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.